Existing users please login

Forgot Password

    Home / Markets / Industries / Health Care

    Tuesday, November 17, 2009

    Novartis: Smaller Flu-vaccine Doses Suffice

    | Respond to Editor | Print

     
    By Robert Daniel
    MarketWatch Pulse
       

      TEL AVIV -- Novartis AG, the Basel health-care giant, on Tuesday reported progress from clinical trials of its influenza A (H1N1) vaccine. In clinical trials, a single dose of the vaccine, which is half the currently approved U.S. dose, "fulfilled immune-response criteria associated with protection in adults and the elderly," those who are age 65 and older, the company said in a statement. The data "suggest that many more people could potentially be vaccinated with our current vaccines supply, protecting more people earlier against the current pandemic," said Andrin Oswald, chief executive of Novartis Vaccines & Diagnostics.

      Copyright © 2009 MarketWatch, Inc.

      Fox Business Video


      Last 5 Stocks

      • Ticker
      • Company
      • Price
      • Change
       

      Personal Finance - Investing - Financial News - Business News - Stock Market Quotes & News - Small Business

      Advertise with us | Jobs at FOX Business Network | Internships at FBN

      Terms of use. Privacy Statement. For FOXBusiness.com technical issues write to foxbusinessonline@foxbusiness.com; for all other feedback, write to feedback@foxbusiness.com.

      Quotes delayed at least 15 minutes. Market Data provided by Interactive Data (Terms & Conditions). Powered and implemented by Interactive Data Managed Solutions. Company fundamental data provided by Morningstar. Earnings estimates data provided by Zacks. Mutual fund data provided by Lipper. Economic data provided by Econoday. Dow Jones & Company Terms & Conditions.

      This material may not be published, broadcast, rewritten, or redistributed. ©2010 FOX News Network, LLC. All rights reserved.